In an internal safety report received through CNN, corporate officials describe how a healthy 37-year-old woman “suffered from transverse myelitis” after receiving her moment dose of the vaccine. He entered the hospital on September 5.
The report describes how the patient won the first dose of the coronavirus vaccine in early June and was fine. He won his dose so far in late August. While running on September 2, he “had a vacation [not a fall] with a jolt. “The report noted that he had no apparent spinal injuries in his examination, according to CNN.
The next day, according to the report, she had difficulty walking, pain and weakness in her arms, pain and decreased sensations in her chest, headaches and decreased ability to use her hands.
The report mentions twice that the woman diagnosed with transverse myelitis “confirmed,” CNN reported. The condition, which can be triggered through viruses, causes inflammation of the spine.
No other similar cases diagnosed in other volunteers examined, according to the report. The woman’s neurologist also noticed that the woman began to feel better.
The report, dated September 10, was sent to doctors administering the study’s clinical trial sites on September 11, CNN reported.
Last week, AstraZeneca announced the volunteer’s “unexplained illness,” and said he postponed trial around the world. British and Brazilian weapons of the trial have resumed ever since; the U. S. branch is in the middle of the U. S. branchUU. no he did.
Dr. Anthony Fauci, director of the U. S. National Institute of Allergy and Infectious Diseases,U. S. , he told CNN this week that “it’s only a matter of time” before rehearsal resumes in the United States. “
He added that he thought the participant’s illness was “punctual” at this stage, and that “it would prevent a trial absolutely on the basis of an adverse singles event. “
He said doctors who run U. S. test sites have been told that the U. S. test sites are not going to be able to do so. But it’s not the first time They will be asked to look for symptoms. ” You have to be especially careful and be careful to see if it happens again, and if it happens, it becomes a completely different situation,” he told CNN. .
Coronavirus distribution plan revealed
Meanwhile, the main points of a plan to temporarily deliver a long-term coronavirus vaccine to Americans were revealed through federal officials wednesday.
Two of the key elements of the plan are to start distributing a vaccine with 24 hours of emergency approval or approval and offering the vaccine for free, the New York Times reported.
Officials of Operation Warp Speed, the effort of several agencies to temporarily vaccinate Americans opposing coronavirus, also said the timing of vaccination is not yet clear, the Times reported, despite repeated statements by President Donald Trump that an injection may be only in office before the November 3 election.
“We are dealing with a world of wonderful uncertainty. We don’t know when we’re going to get a vaccine, we don’t know the amounts, we don’t know the effectiveness of those vaccines,” Paul Mango al Times, the Deputy Director of Policy Staff at the U. S. Department of Health and Human Services, said. “Nice stay” It is an ordinary company, logistically complex and with a lot of uncertainty right now. I think the message we need you to leave is: we’re ready for all those uncertainties. “
Who will get the vaccine first? The initial distribution of a vaccine, in all likelihood in an emergency, would be aimed at a limited organization of high-priority people, such as fitness workers, in the last 3 months of this year and next, the Times reported. The defense is offering logistics for the shipment and garage of the vaccine, and to locate who won a vaccine and whether or not it won the full doses, the paper said.
To do this, existing databases would be connected so that, for example, a patient who won a vaccine at a public fitness center in January can move to a CVS pharmacy 28 days later in the state and have the confidence to receive the dose at the time of the vaccine. vaccine, the Times reported.
Currently, 3 drug brands are testing candidate vaccines in complex trials in the United States. One of the companies, Pfizer, said it could request emergency approval starting in October, while the other two, Moderna and AstraZeneca, said yes. hoping to have something before the end of the year.
Signaling that Pfizer vaccine trials are going smoothly, German pharmaceutical company BioNTech, which is preparing a coronavirus vaccine with Pfizer, announced Thursday that it will buy a new production plant in order to increase production of a COVID-19 vaccine if necessary. . , CNN reported.
The vaccine plant in Marburg, Germany, would produce tens of millions more doses of vaccines according to the month, pending regulatory approval, CNN reported. The plant is expected to be inconsistent with the current one until the first part of 2021, BioNTech said in a statement. The company will maintain a high professionalism of three hundred workers following the relocation of the Novartis plant later this year.
A new drug can prevent you from severe COVID
A single infusion of an experimental drug reduces the degrees of coronavirus in the bodies of newly inflamed patients and reduces their chances of hospitalization, the drug manufacturer reported on Wednesday.
Eli Lilly’s announcement came with detailed knowledge and has still been peer reviewed or published, the Times reported.
The news comes from the intermediate effects of a trial sponsored through Eli Lilly and the US National Institutes of Health. But it’s not the first time NIH officials would comment on the announcement until they saw a more detailed understanding of the trial, the Times reported.
How does the drug paint its magic? It is a monoclonal antibody, a synthetic copy of an antibody produced through a patient who has recovered from COVID-19, the Times reported. Scientists around the world have high hopes that monoclonal antibodies will turn out to be hard remedies for coronaviruses, but they have a caveat: they are difficult to manufacture and it would take time to produce them, the Times reported.
In the trial, 452 newly diagnosed COVID patients gained a monoclonal antibody or placebo infusion. Approximately 1. 7% of those who won the drug were hospitalized and 6% of those who gained a placebo, a 72% risk relief, Lilly said. .
At the same time, blood levels of coronavirus decreased between those who won the drug and their symptoms were less and milder, the Times reported.
This is the first remedy for patients who are not yet seriously ill and hospitalized, the newspaper added.
Dr. Myron Cohen, director of the Institute of Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, told The Times that he was inspired by the results.
“It’s exciting,” said Cohen, who did not participate in the studio. The trial appears to be rigorous and the effects are “really convincing,” he added. Other monoclonal antibody drugs are being developed to combat coronavirus, he noted.
“He’s opening a door, ” said Cohen.
He keeps going up
On Friday, the number of coronavirus cases in the United States exceeded 6. 6 million, with more than 197,500 deaths, according to a Times count.
According to the same count, the five most sensitive states in Friday’s coronavirus cases were: California with nearly 777,000; Texas with more than 710,000; Florida with more than 674,000; New York with almost 452,000; Georgia with more than 284,000 inhabitants.
Stopping coronavirus in the rest of the world remains a challenge.
The number of coronavirus cases in India had exceeded 5. 2 million by Friday, a month after reaching the 3 million mark, the Times reported.
More than 84,000 coronavirus patients have died in India; however, measured as a proportion of the population, the country has noticed fewer deaths than many others, reflecting India’s younger, leaner population.
However, the country’s public fitness formula is under great pressure and some patients with fitness problems cannot find a hospital bed, according to the newspaper. Only the United States has more cases of coronavirus.
Meanwhile, Brazil recorded more than 4. 4 million cases and nearly 135,000 deaths on Friday, according to the Times count.
Cases are also expanding in Russia: the number of coronavirus cases in the country has exceeded one million, the Times reported. On Friday, the death toll in Russia exceeds 19,000.